Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors

Tiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, Maria Ferrantini, Enrica Montefiore, Francesca Urbani, Roberto Patuzzo, Elisabetta Pennacchioli, Mario Santinami, Agata Cova, Gloria Sovena, Flavio Arienti, Claudia Lombardo, Arianna Lombardi, Patrizia Caporaso, Stefania D'Atri, Paolo Marchetti, Enzo Bonmassar, Giorgio Parmiani, Filippo BelardelliLicia Rivoltini

Research output: Contribution to journalArticle

Abstract

The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing effects on T-cell and dendritic cell functions, which may suggest a novel use as a vaccine adjuvant. We have carried out a pilot phase I-II trial to determine the effects of IFN-α, administered as an adjuvant of Melan-A/MART-1:26-35(27L) and gp100:209-217(210M) peptides, on immune responses in stage IV melanoma patients. In five of the seven evaluable patients, a consistent enhancement of CD8+ T cells recognizing modified and native MART-1 and gp100 peptides and MART-1 +gp100+ melanoma cells was observed. Moreover, vaccination induced an increase in CD8+ T-cell binding to HLA tetramers containing the relevant peptides and an increased frequency of CD45RA +CCR7- (terminally differentiated effectors) and CD45RA-CCR7- (effector memory) cells. In all patients, treatment augmented significantly the percentage of CD14+ monocytes and particularly of the CD14+CD16+ cell fraction. An increased expression of CD40 and CD86 costimulatory molecules in monocytes was also observed. Notably, postvaccination monocytes from two of the three patients showing stable disease or long disease-free survival showed an enhanced antigen-presenting cell function and capability to secrete IP10/CXCL10 when tested in mixed leukocyte reaction assays, associated to a boost of antigen and melanoma-specific CD8+ T cells. Although further clinical studies are needed to show the adjuvant activity of IFN-α, the present data represent an important starting point for considering a new clinical use of IFN-α and new immunologic end points, potentially predictive of clinical response.

Original languageEnglish
Pages (from-to)4943-4951
Number of pages9
JournalCancer Research
Volume66
Issue number9
DOIs
Publication statusPublished - May 1 2006

Fingerprint

MART-1 Antigen
Dendritic Cells
Monocytes
Melanoma
Immunization
T-Lymphocytes
Peptides
Melanoma-Specific Antigens
Mixed Lymphocyte Culture Test
Medical Oncology
Antigen-Presenting Cells
Disease-Free Survival
Vaccination
Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. / Di Pucchio, Tiziana; Pilla, Lorenzo; Capone, Imerio; Ferrantini, Maria; Montefiore, Enrica; Urbani, Francesca; Patuzzo, Roberto; Pennacchioli, Elisabetta; Santinami, Mario; Cova, Agata; Sovena, Gloria; Arienti, Flavio; Lombardo, Claudia; Lombardi, Arianna; Caporaso, Patrizia; D'Atri, Stefania; Marchetti, Paolo; Bonmassar, Enzo; Parmiani, Giorgio; Belardelli, Filippo; Rivoltini, Licia.

In: Cancer Research, Vol. 66, No. 9, 01.05.2006, p. 4943-4951.

Research output: Contribution to journalArticle

Di Pucchio, T, Pilla, L, Capone, I, Ferrantini, M, Montefiore, E, Urbani, F, Patuzzo, R, Pennacchioli, E, Santinami, M, Cova, A, Sovena, G, Arienti, F, Lombardo, C, Lombardi, A, Caporaso, P, D'Atri, S, Marchetti, P, Bonmassar, E, Parmiani, G, Belardelli, F & Rivoltini, L 2006, 'Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors', Cancer Research, vol. 66, no. 9, pp. 4943-4951. https://doi.org/10.1158/0008-5472.CAN-05-3396
Di Pucchio, Tiziana ; Pilla, Lorenzo ; Capone, Imerio ; Ferrantini, Maria ; Montefiore, Enrica ; Urbani, Francesca ; Patuzzo, Roberto ; Pennacchioli, Elisabetta ; Santinami, Mario ; Cova, Agata ; Sovena, Gloria ; Arienti, Flavio ; Lombardo, Claudia ; Lombardi, Arianna ; Caporaso, Patrizia ; D'Atri, Stefania ; Marchetti, Paolo ; Bonmassar, Enzo ; Parmiani, Giorgio ; Belardelli, Filippo ; Rivoltini, Licia. / Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. In: Cancer Research. 2006 ; Vol. 66, No. 9. pp. 4943-4951.
@article{04acf5f7030a4895acfc4a7e2fcfb614,
title = "Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors",
abstract = "The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing effects on T-cell and dendritic cell functions, which may suggest a novel use as a vaccine adjuvant. We have carried out a pilot phase I-II trial to determine the effects of IFN-α, administered as an adjuvant of Melan-A/MART-1:26-35(27L) and gp100:209-217(210M) peptides, on immune responses in stage IV melanoma patients. In five of the seven evaluable patients, a consistent enhancement of CD8+ T cells recognizing modified and native MART-1 and gp100 peptides and MART-1 +gp100+ melanoma cells was observed. Moreover, vaccination induced an increase in CD8+ T-cell binding to HLA tetramers containing the relevant peptides and an increased frequency of CD45RA +CCR7- (terminally differentiated effectors) and CD45RA-CCR7- (effector memory) cells. In all patients, treatment augmented significantly the percentage of CD14+ monocytes and particularly of the CD14+CD16+ cell fraction. An increased expression of CD40 and CD86 costimulatory molecules in monocytes was also observed. Notably, postvaccination monocytes from two of the three patients showing stable disease or long disease-free survival showed an enhanced antigen-presenting cell function and capability to secrete IP10/CXCL10 when tested in mixed leukocyte reaction assays, associated to a boost of antigen and melanoma-specific CD8+ T cells. Although further clinical studies are needed to show the adjuvant activity of IFN-α, the present data represent an important starting point for considering a new clinical use of IFN-α and new immunologic end points, potentially predictive of clinical response.",
author = "{Di Pucchio}, Tiziana and Lorenzo Pilla and Imerio Capone and Maria Ferrantini and Enrica Montefiore and Francesca Urbani and Roberto Patuzzo and Elisabetta Pennacchioli and Mario Santinami and Agata Cova and Gloria Sovena and Flavio Arienti and Claudia Lombardo and Arianna Lombardi and Patrizia Caporaso and Stefania D'Atri and Paolo Marchetti and Enzo Bonmassar and Giorgio Parmiani and Filippo Belardelli and Licia Rivoltini",
year = "2006",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-05-3396",
language = "English",
volume = "66",
pages = "4943--4951",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Immunization of stage IV melanoma patients with Melan-A/MART-1 and gplOO peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors

AU - Di Pucchio, Tiziana

AU - Pilla, Lorenzo

AU - Capone, Imerio

AU - Ferrantini, Maria

AU - Montefiore, Enrica

AU - Urbani, Francesca

AU - Patuzzo, Roberto

AU - Pennacchioli, Elisabetta

AU - Santinami, Mario

AU - Cova, Agata

AU - Sovena, Gloria

AU - Arienti, Flavio

AU - Lombardo, Claudia

AU - Lombardi, Arianna

AU - Caporaso, Patrizia

AU - D'Atri, Stefania

AU - Marchetti, Paolo

AU - Bonmassar, Enzo

AU - Parmiani, Giorgio

AU - Belardelli, Filippo

AU - Rivoltini, Licia

PY - 2006/5/1

Y1 - 2006/5/1

N2 - The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing effects on T-cell and dendritic cell functions, which may suggest a novel use as a vaccine adjuvant. We have carried out a pilot phase I-II trial to determine the effects of IFN-α, administered as an adjuvant of Melan-A/MART-1:26-35(27L) and gp100:209-217(210M) peptides, on immune responses in stage IV melanoma patients. In five of the seven evaluable patients, a consistent enhancement of CD8+ T cells recognizing modified and native MART-1 and gp100 peptides and MART-1 +gp100+ melanoma cells was observed. Moreover, vaccination induced an increase in CD8+ T-cell binding to HLA tetramers containing the relevant peptides and an increased frequency of CD45RA +CCR7- (terminally differentiated effectors) and CD45RA-CCR7- (effector memory) cells. In all patients, treatment augmented significantly the percentage of CD14+ monocytes and particularly of the CD14+CD16+ cell fraction. An increased expression of CD40 and CD86 costimulatory molecules in monocytes was also observed. Notably, postvaccination monocytes from two of the three patients showing stable disease or long disease-free survival showed an enhanced antigen-presenting cell function and capability to secrete IP10/CXCL10 when tested in mixed leukocyte reaction assays, associated to a boost of antigen and melanoma-specific CD8+ T cells. Although further clinical studies are needed to show the adjuvant activity of IFN-α, the present data represent an important starting point for considering a new clinical use of IFN-α and new immunologic end points, potentially predictive of clinical response.

AB - The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing effects on T-cell and dendritic cell functions, which may suggest a novel use as a vaccine adjuvant. We have carried out a pilot phase I-II trial to determine the effects of IFN-α, administered as an adjuvant of Melan-A/MART-1:26-35(27L) and gp100:209-217(210M) peptides, on immune responses in stage IV melanoma patients. In five of the seven evaluable patients, a consistent enhancement of CD8+ T cells recognizing modified and native MART-1 and gp100 peptides and MART-1 +gp100+ melanoma cells was observed. Moreover, vaccination induced an increase in CD8+ T-cell binding to HLA tetramers containing the relevant peptides and an increased frequency of CD45RA +CCR7- (terminally differentiated effectors) and CD45RA-CCR7- (effector memory) cells. In all patients, treatment augmented significantly the percentage of CD14+ monocytes and particularly of the CD14+CD16+ cell fraction. An increased expression of CD40 and CD86 costimulatory molecules in monocytes was also observed. Notably, postvaccination monocytes from two of the three patients showing stable disease or long disease-free survival showed an enhanced antigen-presenting cell function and capability to secrete IP10/CXCL10 when tested in mixed leukocyte reaction assays, associated to a boost of antigen and melanoma-specific CD8+ T cells. Although further clinical studies are needed to show the adjuvant activity of IFN-α, the present data represent an important starting point for considering a new clinical use of IFN-α and new immunologic end points, potentially predictive of clinical response.

UR - http://www.scopus.com/inward/record.url?scp=33646400810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646400810&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3396

DO - 10.1158/0008-5472.CAN-05-3396

M3 - Article

C2 - 16651452

AN - SCOPUS:33646400810

VL - 66

SP - 4943

EP - 4951

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -